Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Elicio Therapeutics, Inc.NASDAQ: ELTX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$289K, compared with -$278K a year earlier. Trailing-twelve-month gross profit was -$289K.

Context

  • Gross profit grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$289K or moves back toward the trailing-twelve-month quarterly average of -$72.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$289K— QoQ
Last fiscal yearDec 2025
-$1.13M+4.2% YoY
LTMMar 2026
-$289K+75.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.0%——
1 year+4.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.13M) USD
Year-over-year change
+4.2%

Gross Profit vs competitors

How ELTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +75.2% is the 4th highest of 6, against a peer median of +91.8%.
ELTX Competitors
Gross Profit for ELTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.01M USD+150.7%—94.9%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.69M USD—-34.1%94.7%
ACTUActuate Therapeutics IncLTM Mar 2026$0 USD———
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$149K USD+99.1%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$289K USD+75.2%——
PEPGPepGen Inc.LTM Mar 2026-$1.72M USD-351.6%——
NKTXNkarta, Inc.LTM Mar 2026-$2.34M USD———
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$11.06M USD-20.7%+15.4%2105.7%
Peer median (excluding ELTX) —+91.8%-9.3%94.9%

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.31M0000
Cost of Revenue1.23M1.06M1.17M1.18M1.13M
Gross Profit27.08M(1.06M)(1.17M)(1.18M)(1.13M)
Gross Margin95.6%————
Research & Development48.61M17.05M22.68M33.66M24.9M
Selling, General & Admin17.78M5.63M11.9M11.33M12.81M
Operating Expenses66.39M22.68M34.58M43.81M36.59M
Depreciation & Amortization801K1.06M1.17M1.18M1.13M
EBITDA(51.93M)(23.55M)(32.97M)(50.27M)(37.31M)
EBITDA Margin-183.4%————
Operating Income(39.31M)(23.73M)(35.75M)(44.99M)(37.71M)
Operating Margin-138.8%————
Interest Income3.39K64.83K373K777K776K
Interest Expense876.44K3.6M1.06M455K1.13M
Other Income / Expenses(15.27M)(4.48M)550K(6.91M)(1.86M)
Income Before Tax(54.57M)(28.21M)(35.2M)(51.9M)(39.57M)
Pre-Tax Margin-192.8%————
Income Tax Expense00000
Net Income(26.4M)(28.21M)(35.2M)(51.9M)(39.57M)
Net Margin-93.2%————
EPS (Basic)(19.32)(9.10)(6.96)(4.25)(2.58)
EPS (Diluted)(19.32)(9.10)(6.96)(4.25)(2.58)
Weighted Avg Shares3.2M3.1M5.06M12.2M15.31M
Weighted Avg Shares (Diluted)3.2M3.1M5.06M12.2M15.31M

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.